Summary of The Joint Corporation Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: Increased by 14% year-over-year to $15.2 million.

Adjusted EBITDA: Rose to $1.5 million from $88,000 in Q2 2025, reflecting improved operating leverage.

Consolidated Net Income: Increased to $653,000 compared to $93,000 in the prior year.

Cash Flow: Cash flow from operating activities grew 152% year-over-year to $2.2 million, resulting in free cash flow of $1.9 million.

System-wide Sales: Declined by 3.7% year-over-year to $128 million; comparable sales (comp sales) were down 2.8%, though this was an improvement from the previous quarter.

2Strategic Updates and Business Highlights

Joint 2.0 Initiative: Continued execution aimed at transitioning to a capital-light, pure-play franchisor model.

Refranchising Progress: Significant advancements in refranchising efforts, with ownership transfers for 32 clinics in Southern California and ongoing management service agreements for others.

Patient Retention: Achieved the best quarterly retention rate in over five years due to new flexible plan options.

Capital Allocation: Disciplined approach with $677,000 in share repurchases and investments in business growth, including regional developer territory buybacks.

Marketing Strategy: Focus on digital marketing optimization and personalized patient experiences to drive new patient acquisition and retention.

3Forward Guidance and Outlook

Full-Year 2026 Guidance: Reiterated expectations for system-wide sales between $519 million and $552 million, comp sales ranging from negative 3% to positive 3%, and consolidated adjusted EBITDA of $12.5 million to $13.5 million.

Clinic Openings: Expected to open 22 to 26 new clinics, down from previous guidance of 30 to 35, with a net decrease in clinic count anticipated by year-end.

4Bad News, Challenges, or Points of Concern

Comp Sales Decline: Despite improvements, comp sales were still negative, indicating ongoing challenges in sales performance.

System-wide Sales Decline: A 3.7% year-over-year decrease in system-wide sales raises concerns about overall market performance.

Cost Increases: Selling and marketing expenses surged by 40%, indicating increased investment but also potential pressure on margins.

Refranchising Complexity: The lengthy process of transferring ownership and lease assignments may delay the full benefits of the refranchising strategy.

5Notable Q&A Insights

Digital Marketing Strategy: The company is adapting to changes in AI-driven search environments through local franchisee feedback and dedicated digital marketing resources.

Lapsed Patients: The primary reasons for patient lapses were identified as pain resolution, time constraints, and cost considerations. The company is targeting lapsed patients with tailored marketing efforts.

Comp Performance Trends: Comp sales showed slight improvement towards the end of Q2 and into July, suggesting a potential upward trend.

Pricing Impact: Recent pricing initiatives contributed low single-digit benefits to revenue, with expectations for further improvements in the second half of the year as more clinics adopt new pricing structures. Overall, The Joint Corporation demonstrated solid progress in its strategic initiatives, particularly in refranchising and patient retention, while facing challenges in comp sales and system-wide sales performance. The company remains optimistic about its future growth trajectory and operational improvements.